Za­vante hits the fin­ish line, de­clar­ing a piv­otal win for its an­tibi­ot­ic now head­ed (even­tu­al­ly) to the FDA

Za­vante CEO Ted Schroed­er

The team at Za­vante Ther­a­peu­tics had a very sim­ple goal.

Armed with $45 mil­lion in in­vestor back­ing, they took a broad spec­trum an­tibi­ot­ic that’s been used in var­i­ous coun­tries around the world — out­side the US — and put it through a late-stage, head-to-head, non-in­fe­ri­or­i­ty tri­al against a com­bo an­tibi­ot­ic that’s al­ready in use in the US.

And they are claim­ing a win, prep­ping an FDA ap­pli­ca­tion now for a new an­tibi­ot­ic in an in­creas­ing­ly drug-re­sis­tant world as they con­sid­er their op­tions: mar­ket­ing it them­selves or sell­ing it to a play­er in the field.

By the time they get through the NDA process, CEO Ted Schroed­er tells me, they will have spent “every nick­el” of their $45 mil­lion.

In­ves­ti­ga­tors re­cruit­ed 465 pa­tients, giv­ing their an­tibi­ot­ic Zolyd (fos­fomycin for in­jec­tion, or ZTI-01) in 1-hour IV in­fu­sions three times a day ver­sus a some­what small­er dose of IV piperacillin (peni­cillin)/tazobac­tam at the same sched­ule.

Here is the bot­tom line, pre­sent­ed by Za­vante:

In the study, ZOLYD met the pri­ma­ry end­point of sta­tis­ti­cal non-in­fe­ri­or­i­ty com­pared to piperacillin/tazobac­tam, with an over­all suc­cess rate of 64.7% (119/184 pa­tients) ver­sus 54.5% (97/178 pa­tients), re­spec­tive­ly, a treat­ment dif­fer­ence of 10.2% (95% CI: -0.4, 20.8). Clin­i­cal cure rates were high and sim­i­lar be­tween treat­ment groups (90.8% vs. 91.6%, re­spec­tive­ly).

Fos­fomycin was launched in Spain and then start­ed mak­ing the rounds un­til Big Phar­ma in­tro­duced new class­es of an­tibi­otics and ba­si­cal­ly de­clared the prob­lem of an­tibi­ot­ic de­vel­op­ment fixed, says Schroed­er, a long­time biotech ex­ec with a lengthy stint at Elan on the re­sume. Then those main­stream an­tibi­otics dom­i­nat­ed the mar­ket un­til drug re­sis­tance be­gan to be­come a se­ri­ous threat. And fos­fomycin be­gan to make a come­back, at­tract­ing his at­ten­tion as a like­ly can­di­date for a first-US ap­proval.

The key, he adds, was the pas­sage of the GAIN Act, which gives this an­tibi­ot­ic a shot at eight years of mar­ket ex­clu­siv­i­ty.

Schroed­er says he and his team have the ex­pe­ri­ence to field this an­tibi­ot­ic them­selves. Or they might sell it, as seems the most like­ly suc­cess­ful out­come. An ap­pli­ca­tion will have to wait un­til H1 2018, so they can fin­ish the work.

It’s a big mar­ket, says Schroed­er, but it’s al­so a mar­ket dom­i­nat­ed by cheap, old an­tibi­otics. Schroed­er, though, feels that his an­tibi­ot­ic could come in­to fre­quent play as a com­bo, tied to oth­er an­tibi­otics as in­ten­sive care physi­cians look for a knock­out blow against in­fec­tions.

“I do think its a re­al­ly in­ter­est­ing op­por­tu­ni­ty to bring such a use­ful prod­uct for­ward in such an ef­fi­cient way,” says the CEO. Now he has to com­plete the process.

“In an en­vi­ron­ment of rapid­ly in­creas­ing re­sis­tance, safe and ef­fec­tive an­tibi­otics with ac­tiv­i­ty against MDR pathogens are sore­ly need­ed,” said Kei­th Kaye, Pro­fes­sor of Med­i­cine, Uni­ver­si­ty of Michi­gan. “If ap­proved, ZOLYD’s unique mech­a­nism of ac­tion and broad spec­trum of ac­tiv­i­ty would add to the treat­ment ar­ma­men­tar­i­um when treat­ing se­ri­ous­ly ill pa­tients in the hos­pi­tal.”

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.

Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its board. “Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market,” said Seer chief and founder Omid Farokhzad in a statement.

Daniel O'Day

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

Gilead CEO Daniel O’Day’s new task hunting up a CSO for the company isn’t stopping the industry’s dominant antiviral player from doing pipeline deals.

The big biotech today snapped up 3 preclinical antiviral programs from pharma giant Novartis, with drugs promising to treat human rhinovirus, influenza and herpes viruses. We don’t know what the upfront is, but the back end has $291 million in milestones baked in.

Vas Narasimhan, AP Images

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

Novartis CEO Vas Narasimhan is living in the sweet spot right now.

The numbers are running a bit better than expected, the pipeline — which he assembled as development chief — is performing and the stock popped more than 4% on Thursday as the executive team ran through their assessment of Q2 performance.

Year-to-date the stock is up 28%, so the investors will be beaming. Anyone looking for chinks in their armor — and there are plenty giving it a shot — right now focus on payer acceptance of their $2.1 million gene therapy Zolgensma, where it’s early days. And CAR-T continues to underperform, but Novartis doesn’t appear to be suffering from it.

So what could go wrong?

Actually, not much. But Tim Anderson at Wolfe pressed Narasimhan and his development chief John Tsai to pick which of two looming Phase III readouts with blockbuster implication had the better odds of success.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.